Monopar Therapeutics (MNPR) income statement
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$70.75−0.31 (-0.44%)
Close on Nov 18, 2026Market cap $474.89MP/E –Yield –
Monopar Therapeutics income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -14.2%
Financial strength
- Current ratio
- 33.56
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1313.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.63
- Dividend yield
- –
See a number that looks wrong?